Download PDF
Exp Clin Endocrinol Diabetes 2013; 121(10): 588-594
DOI: 10.1055/s-0033-1355385
Review
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Disorders of Hemostasis in Overt and Subclinical Hypercortisolism

R. Świątkowska-Stodulska
1   Department of Endocrinology and Internal Medicine, Medical university of Gdańsk, Gdańsk, Poland
,
K. Sworczak
1   Department of Endocrinology and Internal Medicine, Medical university of Gdańsk, Gdańsk, Poland
› Author Affiliations
Further Information

Publication History

received 17 May 2013
first decision 08 August 2013

accepted 30 August 2013

Publication Date:
25 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Glucocorticoids are a group of hormones of a particular impact on hemostasis. Epidemiological studies show an approximately severalfold greater incidence of thromboembolic events in hypercortisolemic patients compared to those without hormonal disorders. The prothrombotic action of this steroid class is caused by both the direct impact of hypercortisolism on the activation of coagulation and the inhibition of fibrinolysis, as well as, the pathology of hemostasis due to metabolic disorders, which occur in this endocrinopathy. The aim of this study was to discuss the hemostasis abnormalities that occur in patients with overt and subclinical hypercortisolism with a particular emphasis on plasmatic coagulation, endogenous anticoagulation system, homocysteine and proinflammatory cytokines.

Key words

hemostasis - coagulation - fibrinolysis - hypercortisolism - subclinical Cushing’s ­syndrome
 

  • References

  • 1 Świątkowska-Stodulska R, Babińska A, Sworczak K. Effect of selected hormones on particular parameters of hemostasis. Wiad Lek 2007; 60: 390-393 [Polish]
    PubMedGoogle Scholar
  • 2 Świątkowska-Stodulska R, Babińska A, Sworczak K. Hypercortisolism and hemostasis. Pol Merk Lek 2009; 152: 142-144 [Polish]
    PubMedGoogle Scholar
  • 3 Small M, Lowe GD, Forbes CD et al. Thromboembolic complications in Cushing’s syndrome. Clin Endocrinol (Oxf) 1983; 19: 503-511
    CrossrefPubMedGoogle Scholar
  • 4 Brotman DJ, Girod JP, Posch A et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 2006; 118: 247-252
    CrossrefPubMedGoogle Scholar
  • 5 Van Zaane B, Nur E, Squizzato A et al. Hypercoagulable state in Cushing’s syndrome: a systematic review. J Clin Endocrinol Metab 2009; 94: 2743-2750
    CrossrefPubMedGoogle Scholar
  • 6 Stuijver DJ, van Zaane B, Feelders RA et al. Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011; 96: 3525-3532
    CrossrefPubMedGoogle Scholar
  • 7 Casonato A, Pontara E, Boscaro M et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul Fibrinolysis 1999; 10: 145-151
    CrossrefPubMedGoogle Scholar
  • 8 Dal Bo Zanon R, Fornasiero L, Boscaro M et al. Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb Haemost 1982; 47: 116-117
    PubMedGoogle Scholar
  • 9 Chopra A, Kumar R, Kishore K et al. Blood Coagul Fibrinolysis. Effect of glucocorticoids on von Willebrand factor levels and its correlation with von Willebrand factor gene promoter polymorphism. 2012; 23: 514-519
    PubMedGoogle Scholar
  • 10 Jacoby RC, Owings JT, Ortega T et al. Biochemical basis for the hypercoagulable state seen in Cushing syndrome. Arch Surg 2001; 136: 1003-1006
    CrossrefPubMedGoogle Scholar
  • 11 Patrassi GM, Dal Bo Zanon R, Boscaro M et al. Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb Haemost 1985; 54: 518-520
    PubMedGoogle Scholar
  • 12 Patrassi GM, Sartori MT, Viero ML et al. The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 789-793
    CrossrefPubMedGoogle Scholar
  • 13 Rosenfeld BA, Faraday N, Campbell D et al. Hemostatic effects of stress hormone infusion. Anesthesiology 1994; 81: 1116-1126
    CrossrefPubMedGoogle Scholar
  • 14 Kastelan D, Dusek T, Kraljevic I et al. Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009; 36: 70-74
    CrossrefPubMedGoogle Scholar
  • 15 Daidone V, Boscaro M, Pontara E et al. New insight into the hypercoagulability of Cushing’s syndrome. Neuroendocrinology 2011; 93: 121-125
    CrossrefPubMedGoogle Scholar
  • 16 Hayashi R, Wada H, Ito K et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004; 500: 51-62
    CrossrefPubMedGoogle Scholar
  • 17 Trementino L, Arnaldi G, Appolloni G et al. Coagulopathy in Cushing’s syndrome. Neuroendocrinology 2010; 92 (Suppl. 01) 55-59
    CrossrefPubMedGoogle Scholar
  • 18 Manetti L, Bogazzi F, Giovannetti C et al. Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing’s syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 2010; 163: 783-791
    CrossrefPubMedGoogle Scholar
  • 19 Boscaro M, Sonino N, Scarda A et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 2002; 87: 3662-3666
    CrossrefPubMedGoogle Scholar
  • 20 Erem C, Nuhoglu I, Yilmaz M et al. Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009; 32: 169-174
    CrossrefPubMedGoogle Scholar
  • 21 Fatti LM, Bottasso B, Invitti C et al. Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J Endocrinol Invest 2000; 23: 145-150
    CrossrefPubMedGoogle Scholar
  • 22 Jilma B, Cvitko T, Winter-Fabry A et al. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost 2005; 94: 797-801
    PubMedGoogle Scholar
  • 23 Terzolo M, Allasino B, Bosio S et al. Hyperhomocysteinemia in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2004; 89: 3745-3751
    CrossrefPubMedGoogle Scholar
  • 24 Faggiano A, Melis D, Alfieri R et al. Sulfur Amino Acids in Cushing’s Disease: Insight in Homocysteine and taurine levels in patients with Active and Cured disease. J Clin Endocrinol Metab 2005; 90: 6616-6622
    CrossrefPubMedGoogle Scholar
  • 25 Di Minno MN, Tremoli E, Coppola A et al. Homocysteine and arterial thrombosis: challenge and opportunity. Thromb Haemost 2010; 103: 942-961
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Eldibany MM, Caprini AJ. Hyperhomocyteinemia and thrombosis. An overview. Arch Pathol Lab Med 2007; 131: 872-884
    PubMedGoogle Scholar
  • 27 Nonaka H, Tsujino T, Watari Y et al. Taurine prevents the decrease in expression and secretion of extracellular superoxide dismutase induced by homocysteine: amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001; 104: 1165-1170
    CrossrefPubMedGoogle Scholar
  • 28 Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 513-523
    CrossrefPubMedGoogle Scholar
  • 29 Folsom AR, Qamhieh HT, Wing RR et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-169
    CrossrefPubMedGoogle Scholar
  • 30 Juhan-Vague I, Alessi MC, Mavri A et al. Plasminogen activator-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579
    CrossrefPubMedGoogle Scholar
  • 31 Kohler HP. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 241-252
    PubMedGoogle Scholar
  • 32 Mutch NJ, Wilson HM, Booth NA. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 2001; 60: 341-347
    CrossrefPubMedGoogle Scholar
  • 33 Steinberg HO, Chaker H, Leaming R et al. Obesity/Insulin resistance in associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610
    CrossrefPubMedGoogle Scholar
  • 34 Vamberque A, Rugeri L, Gaveriaux V et al. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001; 101: 367-375
    CrossrefPubMedGoogle Scholar
  • 35 Meigs JB, Mittleman MA, Nathan DM et al. Hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228
    CrossrefPubMedGoogle Scholar
  • 36 De Pergola G, De Mitrio V, Giorgino F et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997; 21: 527-535
    CrossrefPubMedGoogle Scholar
  • 37 Westerbacka J, Yki-Jarvinen H, Turpeinen A et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 2002; 22: 167-172
    CrossrefPubMedGoogle Scholar
  • 38 Kerachian MA, Cournoyer D, Harvey EJ et al. Effect of high-dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion. Steroid Biochem Mol Biol 2009; 116: 127-133
    CrossrefPubMedGoogle Scholar
  • 39 van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-5529
    CrossrefPubMedGoogle Scholar
  • 40 Morange PE, Aubert J, Peiretti F et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 890-895
    CrossrefPubMedGoogle Scholar
  • 41 Halleux CM, Declerck PJ, Tran SL et al. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 4097-4105
    CrossrefPubMedGoogle Scholar
  • 42 Kristo C, Ueland T, Godang K et al. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing’s syndrome. J Endocrinol Invest 2000; 31: 400-4055
    PubMedGoogle Scholar
  • 43 Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
    CrossrefPubMedGoogle Scholar
  • 44 Kern PA, Ranganathan S, Li C et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: 745-751
    PubMedGoogle Scholar
  • 45 De Pergola G, Pannacciulli N. Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002; 25: 899-904
    PubMedGoogle Scholar
  • 46 Skurk T, van Harmelen V, Lee YM et al. Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. Horm Metab Res 2002; 34: 659-663
    Article in Thieme ConnectPubMedGoogle Scholar
  • 47 Natali A, Toschi E, Baldeweg S et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006; 55: 1133-1140
    CrossrefPubMedGoogle Scholar
  • 48 Maruna P, Marunová M, Owen K. Changes in levels of acute phase proteins in patients with central hypercortisolism. Cas Lek Cesk 2002; 141: 207-210
    PubMedGoogle Scholar
  • 49 Watanobe H, Tamura T, Habu S et al. Measurement of cytokines in the cavernous sinus plasma from patients with Cushing’s disease. Neuropeptides 1998; 32: 119-123
    CrossrefPubMedGoogle Scholar
  • 50 Chan P, Huang TY, Shieh SM et al. Thrombophilia in Patients with Hypertriglyceridemia. J Thromb Thrombolysis 1997; 4: 425-429
    CrossrefPubMedGoogle Scholar
  • 51 Gnacińska M, Małgorzewicz S, Lysiak-Szydłowska W et al. The serum profile of adipokines in overweight patients with metabolic syndrome. Endokrynol Pol 2010; 61: 36-41
    PubMedGoogle Scholar
  • 52 Gnacińska M, Małgorzewicz S, Guzek M et al. Adipose tissue activity in relation to overweight or obesity. Endokrynol Pol 2010; 61: 160-168
    PubMedGoogle Scholar
  • 53 Vallasi E, Biler BK, Klibanski A et al. Adipokines and Cardiovascular Risk in Cushing’s Syndrome. Neuroendocrinology 2012; 95: 187-206
    CrossrefPubMedGoogle Scholar
  • 54 Konstantinides S, Schäfer K, Koschnick S et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-1540
    CrossrefPubMedGoogle Scholar
  • 55 Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and risk of cardiovascular disease in the west Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056
    CrossrefPubMedGoogle Scholar
  • 56 van der Pas R, Leebeek FW, Hofland LJ et al. Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 2013; 78: 481-488
    CrossrefPubMedGoogle Scholar
  • 57 Morelli V, Masserini B, Salcuni AS et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 2010; 73: 161-166
    PubMedGoogle Scholar
  • 58 Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-1236
    CrossrefPubMedGoogle Scholar
  • 59 Terzolo M, Osella G, Alì A et al. Subclinical Cushing’s syndrome in adrenal incidentaloma. Clin Endocrinol (Oxf) 1998; 48: 89-97
    Google Scholar
  • 60 Terzolo M, Bovio S, Pia A et al. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2009; 23: 233-243
    CrossrefPubMedGoogle Scholar
  • 61 Mazzuco TL, Bourdeau I, Lacroix A. Adrenal incidentalomas and subclinical Cushing’s syndrome: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes 2009; 16: 203-210
    PubMedGoogle Scholar
  • 62 Viscovo L, Nuzzo V, Lombardi G. Subclinical Cushing’s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 2000; 85: 1440-1448
    CrossrefPubMedGoogle Scholar
  • 63 Reincke M. Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000; 29: 43-56
    CrossrefPubMedGoogle Scholar
  • 64 Tauchmanovà L, Rossi R, Biondi B et al. Patients with subclinical Cushing’s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 2002; 87: 4872-4878
    CrossrefPubMedGoogle Scholar
  • 65 Koutroumpi S, Spiezia L, Albiger N et al. Thrombin generation in Cushing’s Syndrome: do the conventional clotting indices tell the whole truth?. Pituitary 2013; [Epub ahead of print]
    PubMedGoogle Scholar
  • 66 Świątkowska-Stodulska R, Kaniuka-Jakubowska S, Wiśniewski P et al. The estimation of selected endogenous anticoagulation system parameters in patients with subclinical Cushing’s syndrome. Eur J Endocrinol 2011; 165: 865-871
    CrossrefPubMedGoogle Scholar
  • 67 Bowles LK, Cooper JA, Howarth DJ et al. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003; 14: 569-573
    CrossrefPubMedGoogle Scholar
  • 68 Kopeć M. Diverse and variable functions of thrombin. Acta Haematol Pol 1997; 28: 95-100 [Polish]
    PubMedGoogle Scholar
  • 69 Kopeć M. Progress in mechanisms of blood coagulation activation. Acta Haematol Pol 1994; 25 (suppl. 2) 5-13 [Polish]
    PubMedGoogle Scholar
  • 70 Zawilska K. Arterial thrombosis risk factors. In: Thrombi and emboli. Red. Łopaciuk S. Wydawnictwo lekarskie PZWL; Warszawa: 1996: 141-151 [Polish]
    Google Scholar
  • 71 Brower MS, Harpel PC. Alpha-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes. Blood 1983; 61: 842-849
    PubMedGoogle Scholar
  • 72 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by alpha 1-antitrypsin. J Biol Chem 1988; 263: 11613-11616
    PubMedGoogle Scholar
  • 73 España F, Gilabert J, Vicente V et al. Activated protein C: alpha 1-antitrypsin (APC: alpha 1 AT) complex as a marker for in vitro diagnosis of prothrombotic states. Thromb Res 1992; 66: 499-508
    CrossrefPubMedGoogle Scholar
  • 74 Świątkowska-Stodulska R, Babińska A, Skibowska-Bielińska A et al. Assessment of α1 antitrypsin and α2 macroglobulin in obese patients. Arch Med Wew 2008; 118: 713-718
    PubMedGoogle Scholar
  • 75 Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)?. Diabetes Metab 2004; 30: 569-572
    CrossrefPubMedGoogle Scholar
  • 76 Faraj M, Messier L, Bastard JP et al. Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia 2006; 49: 1637-1646
    CrossrefPubMedGoogle Scholar
  • 77 Świątkowska-Stodulska R, Kaniuka-Jakubowska S, Wiśniewski P et al. Homocysteine and alpha-1 antitrypsin concentration in patients with subclinical hypercortisolemia. Adv Med Sci 2012; 57: 302-307
    CrossrefPubMedGoogle Scholar